IQ EQ FUND MANAGEMENT IRELAND Ltd Has $145,000 Stock Position in Personalis, Inc. (NASDAQ:PSNL)

IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Personalis, Inc. (NASDAQ:PSNL) by 66.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,168 shares of the company’s stock after buying an additional 10,065 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Personalis were worth $145,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of PSNL. JPMorgan Chase & Co. lifted its holdings in shares of Personalis by 2,827.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock worth $34,000 after acquiring an additional 5,654 shares during the period. Olympiad Research LP acquired a new stake in shares of Personalis during the 4th quarter valued at $59,000. SG Americas Securities LLC acquired a new stake in shares of Personalis during the fourth quarter valued at about $63,000. Raymond James Financial Inc. acquired a new stake in Personalis during the 4th quarter worth approximately $64,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Personalis in the fourth quarter worth $87,000. 61.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the company. Lake Street Capital upped their target price on Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Needham & Company LLC decreased their target price on Personalis from $7.25 to $7.00 and set a “buy” rating for the company in a research report on Friday, February 28th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Personalis in a research note on Friday, February 28th. Finally, Craig Hallum started coverage on Personalis in a research note on Monday, March 17th. They issued a “buy” rating and a $8.00 price objective for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $7.80.

Personalis Price Performance

Shares of Personalis stock opened at $3.62 on Friday. Personalis, Inc. has a 1 year low of $1.14 and a 1 year high of $7.20. The stock has a fifty day moving average price of $4.60 and a 200-day moving average price of $4.80. The firm has a market cap of $319.51 million, a PE ratio of -2.15 and a beta of 1.73.

Personalis (NASDAQ:PSNL) last issued its earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.09. The firm had revenue of $16.80 million for the quarter, compared to analyst estimates of $15.48 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. As a group, equities analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.